BLOG

The Xyzagen Blog

Stay ahead of emerging trends in drug development with Xyzagen’s expert insights, regulatory interpretations, and scientific thought leadership.

Nov 14

Choosing the Right ADA Assay for Ocular Biologics: Ligand Binding vs. Cell-Based Assays

By Heather Mills Blog

Introduction For ophthalmic biologics and gene therapies administered by intravitreal injection, understanding immunogenicity is critical. These therapies can trigger an immune response, leading to the production of anti-drug antibodies (ADAs).…

READ FULL BLOG

Blog

Understanding the Four Key Disciplines Behind Nonclinical PK Studies

Introduction When it comes to bringing new therapies from concept to initial clinical trials, understanding how a drug behaves in…

READ FULL BLOG

2025 Drug Development Trends: The Evolution of Innovation – A Xyzagen Industry Forecast

Introduction The drug development landscape is currently undergoing a major transformation, driven by advanced modeling, real-time bioanalysis, and cutting-edge therapeutic…

READ FULL BLOG

Welcome to Xyzagen: Your Partner in Early Drug Development and Beyond

Who Is Xyzagen? Xyzagen is a boutique, client-focused, consulting and contract research organization (CRO), providing integrated support across the full…

READ FULL BLOG